ClinicalTrials.gg
CompletedNCT01440088Updated Jun 2, 2016

A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

A Phase 3 interventional study of TH-302 in Combination with Doxorubicin and Doxorubicin in Soft Tissue Sarcoma, sponsored by Threshold Pharmaceuticals. Completed at 92 sites in 13 countries. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2016-06-02.

Sponsored by Threshold Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
640
Allocation
Randomized
Ages
15 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies testing doxorubicin in Sarcoma — 13 open to participants now, 14 under way, 2 of them phase 3. Doxorubicin · Sarcoma.

Enrollment
2nd of 60
640 · median 42
Started
2011
the only one that year
Phase 3
9 of 65
1 open now
Registered
38th of 65
by date

Among the 65 studies testing doxorubicin in Sarcoma, this one is the 2nd largest by enrollment of the 60 interventional ones that give a count, is the only one that started in 2011, is one of 9 in phase 3, and was the 38th registered.

Sarcoma

1,609 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

13 of the 65 studies testing doxorubicin in Sarcoma are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About doxorubicin

Doxorubicin: first FDA approval 1974 (DOXORUBICIN HYDROCHLORIDE), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 93 take children under 18; 12 take healthy volunteers.

This study: 15 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies testing doxorubicin in Sarcoma, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether TH-302 in combination with Doxorubicin is safe and effective in the treatment of Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma.

Read the detailed description

TH-302 is designed to target the hypoxic regions of tumors which are generally located distant from tumor vessels. Doxorubicin has poor tissue penetration and targets the regions of tumors that are located in proximity to the tumor vessels. The presence of hypoxia in solid tumors is associated with a more malignant phenotype and resistance to chemotherapy. The hypoxia-activated prodrug, TH-302, is designed to selectively target the hypoxic microenvironment. Soft tissue sarcomas have evidence supporting the presence of hypoxia based on pO2 histography, F-MISO and gene expression profiling. There is an absence of therapeutic options for subjects with soft tissue sarcoma. Combining doxorubicin with TH-302 may enable the targeting of both the normoxic and hypoxic regions of soft tissue sarcoma.

03

Conditions studied

  • Soft Tissue Sarcoma

Browse trials for

Keywords

  • TH-302
  • TH-CR-406
  • SARC021
  • Locally Advanced Soft Tissue Sarcoma
  • Metastatic Soft Tissue Sarcoma
  • Sarcoma
  • Doxorubicin
  • Evofosfamide
04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥ 15 years of age
  • Ability to understand the purposes and risks of the study and has signed or, if appropriate, the subject's parent or legal guardian has signed a written form approved by the investigator's IRB/Ethics Committee
  • confirmed diagnosis of soft tissue sarcoma of the following histopathologic types:

    • Synovial sarcoma
    • High grade fibrosarcoma
    • Undifferentiated sarcoma; sarcoma not otherwise specified (NOS)
    • Liposarcoma
    • Leiomyosarcoma (excluding GIST)
    • Angiosarcoma (excluding Kaposi's sarcoma)
    • Malignant peripheral nerve sheath tumor
    • Pleomorphic Rhabdomyosarcoma
    • Myxofibrosarcoma
    • Epithelioid sarcoma
    • Undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma (MFH) (including pleomorphic, giant cell, myxoid and inflammatory forms)
  • Locally advanced unresectable or disease with no standard curative therapy available and for whom treatment with single agent doxorubicin is considered appropriate.
  • Recovered from reversible toxicities of prior therapy
  • by (RECIST) 1.1
  • (ECOG) performance status of 0 or 1
  • of at least 3 months
  • Acceptable liver, renal, hematological and cardiac function
  • All women of must have a negative serum pregnancy test and all subjects must agree to use effective means of

Exclusion criteria

Exclusion Criteria:

  • Prior systemic therapy for advanced or disease ( therapy followed by surgical resection and adjuvant therapy permitted). Palliative radiotherapy to non-target lesions is allowed if completed at least two weeks prior to study entry
  • Low grade tumors according to standard grading systems
  • Prior therapy with ifosfamide or cyclophosphamide or other nitrogen mustards
  • Prior therapy with an anthracycline or anthracenedione
  • Prior mediastinal/cardiac radiotherapy
  • Current use of drugs with known cardiotoxicity or known interactions with doxorubicin
  • Anti-cancer treatment with radiation therapy, neoadjuvant or adjuvant chemotherapy, targeted therapies, immunotherapy, hormones or other antitumor therapies within 4 weeks prior to study entry (6 weeks for nitrosoureas or mitomycin C). Palliative radiotherapy to non-target lesions is allowed, is completed at least two weeks prior to study entry.
  • Significant cardiac dysfunction precluding treatment with doxorubicin
  • Seizure disorders requiring anticonvulsant therapy unless seizure-free for the last year
  • Known (unless previously treated and well controlled for a period of ≥ 3 months)
  • Previously treated , except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancer from which the subject has been disease-free for at least 5 years
  • Severe chronic obstructive or other pulmonary disease with hypoxemia or in the opinion of the investigator any physiological state likely to cause normal tissue hypoxia
  • Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without complete recovery
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
  • Prior therapy with a hypoxic cytotoxin
  • Subjects who participated in an drug or device study within 28 days prior to study entry
  • Known infection with , , or
  • Subjects who have exhibited allergic reactions to a structural compound similar to TH-302,doxorubicin or their
  • Females who are pregnant or breast-feeding
  • Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
  • Unwillingness or inability to comply with the study protocol for any reason
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
640 participants (actual)

Study arms

  • Experimental
    TH-302 in Combination with Doxorubicin

    Drug: TH-302 in Combination with Doxorubicin

  • Active comparator
    Doxorubicin

    Drug: Doxorubicin

Interventions

  • DrugTH-302 in Combination with Doxorubicin

    Drug pages: TH 302 · Doxorubicin

    300 mg/m2 of TH-302 will be administered by IV infusion over 30-60 minutes on Days 1 and 8 of a 21-day cycle. Doxorubicin may be delivered as a bolus administration or as a continuous infusion administration; administration schedule must be specified prior to enrollment. Doxorubicin bolus administration: 75 mg/m2 administered by bolus injection starting on Day 1 of a 21-day cycle. Doxorubicin continuous administration: 75 mg/m2 administered by continuous IV infusion over 48-96 hours starting on Day 1 of a 21-day cycle. Doxorubicin administration will start between 2 to 4 hours after completion of the TH-302 infusion when used in combination with TH-302.

  • Doxorubicin may be delivered as a bolus administration or as a continuous infusion administration; administration schedule must be specified prior to enrollment. Doxorubicin bolus administration: 75 mg/m2 administered by bolus injection starting on Day 1 of a 21-day cycle. Doxorubicin continuous administration: 75 mg/m2 administered by continuous IV infusion over 48-96 hours starting on Day 1 of a 21-day cycle.

06

What researchers measure

Primary outcomes

  1. Efficacy of TH-302 in combination with doxorubicin

    Efficacy will be determined by overall survival in subjects with locally advanced unresectable or metastatic soft tissue sarcoma previously untreated with chemotherapy compared with doxorubicin alone

    Time frame: 2 years

Secondary outcomes

  1. Safety of TH-302 in combination with doxorubicin in subjects with locally advanced unresectable or metastatic soft tissue sarcoma compared with doxorubicin alone

    To investigate the pharmacokinetics of TH-302, Br-IPM, doxorubicin, and doxorubicinol in plasma

    Time frame: 2 years

07

Study locations

92 sites
  • Mayo Arizona
    Scottsdale, Arizona 85259, United States
  • Arizona Cancer Center
    Tucson, Arizona 85719, United States
  • USC-Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • University of California, Los Angeles
    Los Angeles, California 90095-6901, United States
  • Sarcoma Oncology Center
    Santa Monica, California 90403, United States
  • Stanford Comprehensive Cancer Center
    Stanford, California 94305, United States
  • Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • Washington Cancer Institute
    Washington, District of Columbia 20010, United States
  • South Florida Center for Gynecologic Oncology
    Boca Raton, Florida 33487, United States
  • Mayo Clinic-Florida-Cancer Clinical Studies Unit
    Jacksonville, Florida 32224, United States
  • MD Anderson Cancer Center Orlando
    Orlando, Florida 32806, United States
  • H.Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • Winship Cancer Institute of Emory University, Midtown Campus
    Atlanta, Georgia 30322, United States
  • Kootenai Health - Kootenai Cancer Center
    Coeur d'Alene, Idaho 83814, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Oncology Specialists
    Park Ridge, Illinois 60068, United States
  • Indiana University Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • University of Iowa Health Care - University of Iowa Hospital
    Iowa City, Iowa 52242, United States
  • Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Dana Farber Cancer Institute Center for Sarcoma and Bone Oncology
    Boston, Massachusetts 02215, United States
  • University of Michigan Cancer Center
    Ann Arbor, Michigan 48109, United States
  • Mayo Rochester
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine
    St. Louis, Missouri 63110, United States
  • Montefiore
    Bronx, New York 10461, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10031, United States
  • Columbia University Medical Center
    NY, New York 10032, United States
  • Carolinas Hematology-oncology Associates-Blumenthal Cancer Center
    Charlotte, North Carolina 28203, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Wake Forest University Baptist Medical Center
    Winston Salem, North Carolina 27157, United States
  • University Hospitals Seidman Cancer Center
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • The Arthur G. James Cancer Hospital and Richard J Solove Research Institue, The Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43202, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Pennsylvania Oncology Hematology Associates
    Philadelphia, Pennsylvania 19106, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • University of Pittsburg Medical Center
    Pittsburg, Pennsylvania 15232, United States
  • MUSC - Hollings Cancer Center
    Charleston, South Carolina 29425, United States
  • Vanderbilt-Ingram Cancer Center
    Nashville, Tennessee 37232, United States
  • University of Vermont
    Burlington, Vermont 05405, United States
  • Virginia Commonwealth Universtiy-Massey Cancer Center
    Richmond, Virginia 23298, United States
  • University of Washington Cancer Center
    Seattle, Washington 98109, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • University Klinikum Graz
    Graz, A-8036, Austria
  • Univ. Klinik fur Innere Medizin I Internistische Onkologie Medizinische Universitat Innsbruck
    Innsbruck, A-6020, Austria
  • Allgemeines Krankenhaus Wien
    Wien, A-1090, Austria
  • Universitaire Ziekenhuizen (UZ) Leuven - Gasthuisberg
    Leuven, 3000, Belgium
  • Juravinski Cancer Centre at Hamilton Health Sciences - Department of Medicine
    Hamilton, Ontario L8V5C2, Canada
  • McGill University Health Centre
    Montreal, Quebec H3G 1A4, Canada
  • Tom Baker Cancer Centre
    Calgary, T2N4N2, Canada
  • Cross Cancer Institute
    Edmonton, T6G1Z2, Canada
  • Ottawa Health Research Institue
    Ottawa, K1H8L6, Canada
  • BCCA- Vancouver Cancer Centre - Division of Medical Oncology
    Vancouver, V5Z4E6, Canada
  • Cancer Care Manitoba
    Winnipeg, R3E0V9, Canada
  • University Hospital Herlev at Copenhagen
    Herlev, Copenhagen 2730, Denmark
  • ICO Rene Gauducheau
    Saint Herblain Cedex, Nantes 44805, France
  • Institut Bergonie
    Bordeaux, 33076, France
  • Departement d'Oncologie Medicale
    Dijon, 21079, France
  • Centre Leon Berard
    Lyon, 69008, France
  • Département d'Oncologie Moléculaire, Institut Paoli-Calmettes (IPC) and U119 Inserm
    Marseille, 13009, France
  • Centre Antoine Lacassagne
    Nice, France
  • CHU Strasbourg
    Strasbourg, 67098, France
  • Institut Claudius Regaud
    Toulouse Cedex, 31052, France
  • HELIOS Klinikum Berlin-Buch
    Berlin, 13125, Germany
  • Helios Klinikum Bad Saarow, Department of Hematology, Oncology, and Palliative Care, Sarcoma Center Berlin-Brandenburg
    Berlin, 15526, Germany
  • Universitätsklinikum Essen
    Essen, 45122, Germany
  • Krankenhaus Nordwest GmbH
    Frankfurt, Germany
  • Medizinische Hochschule Hannover (MHH) - Klinik fuer Haemonstaseologie, Onkologie und Stammzelltransplantation
    Hannover, 30625, Germany
  • Div. of Surgical Oncology & Thoracic Surgery, Mannheim University Medical Center
    Mannheim, D-68165, Germany
  • Wilhelm's University, Universitatsklinikum Muenster, Medizinische Klinik und Poliklinik A, Albert-Schweitzer-Campus 1
    Munster, 48149, Germany
  • Magyar Honvedseg Honvedkorhaz, Onkologiai Osztaly
    Budapest, H-1062, Hungary
  • Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet, Megyei Onkologiai Kozpont
    Szolnok, H-5004, Hungary
  • Sharette Institute of Oncology, Hadassah-Hebrew University Medical Center, Hadassah Medical Org-Ein Karem
    Kiryat Hadassah, Jerusalem 91120, Israel
  • IRCCS Centro di Riferimento Oncologico-Struttura Operativa
    Aviano, Pordenone 33081, Italy
  • Fondazione del Piemonte per l'Oncologia, Instituto per la Ricerca e la Cura del cancro (I.R.C.C.), Dipartimento Oncologico, Direzione Operativa Oncologia Medica a Direzione Universitaria
    Candiolo, Torino 10060, Italy
  • Centro di Riferimento Oncologico (CRO)
    Aviano, 33081, Italy
  • Azienda Ospedaliera Garibaldi
    Catania, 95122, Italy
  • Azienda Ospedaliero Universitaria-Policlinico Paolo Giacco
    Palermo, 90127, Italy
  • ASL TO/2 di TORINO_Presidio Sanitario Gradenigo, S.C. di Oncologia
    Torino, 10149, Italy
  • Wojewodzkie Centrum Onkologii
    Gdansk, 80-219, Poland
  • Centrum Onkologii Instytut im M. Sklodowskiej-Curie
    Krakow, 31-115, Poland
  • Centrum Onkologii-Instytut im. M. Sklodowskiej-Curie
    Warszawa, 02-781, Poland
  • GUZ "Regional Oncology Dispensay", Kazan
    Kazan, 420029, Russian Federation
  • ROTSN RAMS them. Н.Н.Блохина NN Blokhin
    Moscow, 115478, Russian Federation
  • FGU Moscow Research Institute of Oncology named after P.A. Hertzen of Rosmedtechnology
    Moscow, 125284, Russian Federation
  • H.U. Canarias, Hospital Universitario de Canarias. Servicio de Oncología Médica
    Tenerife, Canarias 38320, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 08041, Spain
  • Institut Catala d'Oncologia
    Barcelona, 08907, Spain
  • Hospital Sant Joan de Deu, Department de Oncologia
    Barcelona, 08950, Spain
  • Hospital Universitario Ramón y Cajal.
    Madrid, 28034, Spain
  • Universidad Complutense Madrid Facultad de Medicina - Hospital Universitario 12 de Octubre, Servicio de Oncologia Medica Hospital Universitario 12 de Octubre
    Madrid, 28034, Spain
08

References and documents

Publications

  • Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL, Schuetze S, Reed D, Chawla SP, Riedel RF, Krarup-Hansen A, Toulmonde M, Ray-Coquard I, Hohenberger P, Grignani G, Cranmer LD, Okuno S, Agulnik M, Read W, Ryan CW, Alcindor T, Del Muro XFG, Budd GT, Tawbi H, Pearce T, Kroll S, Reinke DK, Schoffski P. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2017 Aug;18(8):1089-1103. doi: 10.1016/S1470-2045(17)30381-9. Epub 2017 Jun 23. Erratum In: Lancet Oncol. 2018 Feb;19(2):e78. doi: 10.1016/S1470-2045(18)30037-8. PubMed 28651927 ↗
  • Chawla SP, Cranmer LD, Van Tine BA, Reed DR, Okuno SH, Butrynski JE, Adkins DR, Hendifar AE, Kroll S, Ganjoo KN. Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. J Clin Oncol. 2014 Oct 10;32(29):3299-306. doi: 10.1200/JCO.2013.54.3660. Epub 2014 Sep 2. PubMed 25185097 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Dec 2015 and a completion of May 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2011
First posted
Sep 26, 2011
Start
Sep 2011
Primary completionActual
Dec 2015
CompletionActual
May 2016
Last update
Jun 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01440088
Lead sponsor
Threshold Pharmaceuticals
Collaborators
Sarcoma Alliance for Research through Collaboration (SARC)
Responsible party
Sponsor
First posted
Sep 26, 2011
Start date
Sep 2011
Primary completion
Dec 2015
Completion
May 2016
Last update
Jun 2, 2016

Study contacts

William Tap, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: TH 302 · Doxorubicin

Start the discussion